Positive-Strand RNA Viral RdRps: From Structure Conservation and Activity Assay to Drug Development.

Publication date: Jun 11, 2026

Positive-strand RNA viruses represented by SARS-CoV-2 and DENV spread globally with high infectivity and frequent mutations, posing a severe threat to human health. However, specific and effective antiviral drugs remain limited. RNA-dependent RNA polymerase (RdRp) plays a critical role in the genome replication of RNA viruses and shows high structural conservation. No homologous protein exists in human cells, making RdRp an effective, safe, and broad-spectrum antiviral target. Therefore, establishing an RdRp activity assay for drug development based on its mechanism is of great significance. This paper summarizes the structural characteristics of RdRp and the methods for constructing RdRp activity assay, especially for cell-free activity assay. In addition, several reported RdRp inhibitors and their pharmaceutical progress are also reviewed, aiming to provide a reference for the development of novel antiviral drugs targeting RdRp.

Open Access PDF

Concepts Keywords
Effective Antiviral Agents
Genome Antiviral Agents
Inhibitors Drug Development
Polymerase Humans
Viruses Positive-Strand RNA Viruses
positive-stranded RNA virus
RdRp assay
RdRp inhibitor
RNA Replication
RNA-Dependent RNA Polymerase
RNA-Dependent RNA Polymerase
SARS-CoV-2
Virus Replication

Semantics

Type Source Name
pathway KEGG RNA polymerase
drug DRUGBANK Coenzyme M
disease MESH hepatitis
disease MESH dengue
disease MESH Severe acute respiratory syndrome
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH NS5
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK Serine
drug DRUGBANK Glycine
drug DRUGBANK Amino acids
disease MESH dissociation
pathway KEGG Viral replication
drug DRUGBANK ANX-510
disease MESH strain
disease MESH EVC
disease MESH NS3
drug DRUGBANK L-Tyrosine
drug DRUGBANK Uridine
drug DRUGBANK Gold
drug DRUGBANK Zinc
drug DRUGBANK Guanosine
disease MESH infection
drug DRUGBANK Biotin
drug DRUGBANK Urea
drug DRUGBANK ATP
pathway REACTOME Translation
pathway KEGG Ribosome
disease MESH cap
drug DRUGBANK Alkaline Phosphatase
drug DRUGBANK Phosphate ion
disease MESH diarrhea
drug DRUGBANK Ribavirin
drug DRUGBANK Sofosbuvir
drug DRUGBANK Favipiravir
drug DRUGBANK Dasabuvir
disease MESH Influenza
drug DRUGBANK Adenosine
disease MESH virus infections
disease MESH emergency
disease MESH Lassa fever
disease MESH rabies
disease MESH COVID 19
drug DRUGBANK Pipendoxifene
drug DRUGBANK Suramin
drug DRUGBANK Water
disease MESH Japanese encephalitis
drug DRUGBANK beta-Sitosterol
drug DRUGBANK Violaxanthin
drug DRUGBANK Rutin
drug DRUGBANK Guanidine
drug DRUGBANK MK-212
disease MESH CPP
disease MESH Infectious Diseases
disease MESH Flavivirus Infections
disease MESH Dis
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Ito
disease MESH Picornavirus Infection
disease MESH Pain
pathway REACTOME Neddylation
disease MESH NHC
disease MESH STAR
pathway REACTOME Metabolism
drug DRUGBANK Efavirenz
drug DRUGBANK Tipranavir
drug DRUGBANK Ombitasvir
drug DRUGBANK Kale
drug DRUGBANK Ledipasvir
drug DRUGBANK Daclatasvir
drug DRUGBANK Simeprevir
drug DRUGBANK Paritaprevir
drug DRUGBANK Troleandomycin
drug DRUGBANK Carboxyamidotriazole
disease MESH Norovirus Infection
disease MESH Park
disease MESH Gan
disease MESH injury

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *